Threshold grants OBI ex-Asian rights to TH-3424

OBI Pharma Inc. (TPEx:4174) acquired ex-Asian development and commercialization rights to OBI-3424 (formerly TH-3424) from Threshold Pharmaceuticals Inc. (NASDAQ:THLD) for an undisclosed upfront payment. OBI receives rights worldwide, excluding Taiwan, Japan, South Korea, Singapore, Malaysia, Thailand, Turkey, India and China, including Hong Kong and Macao.

OBI-3424 is in preclinical testing to treat hepatocellular carcinoma (HCC), castration-resistant prostate cancer (CRPC) and acute lymphoblastic leukemia (ALL). OBI plans to submit an IND for the product in early 2018...